Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

Integrity Dividend Harvest Fund earns an Average Process Pillar rating. The most important driver of the rating is the fund's impressive long-term risk-adjusted performance. This can be seen in ...

Stock futures rebound as key movers like Calix soar on strong Q1 results, while Medpace, Novo Nordisk, and Zion struggle amid mixed guidance and competition.